Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neuromuscular disorders

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    73 result(s) found for: Neuromuscular disorders. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2013-002362-39 Sponsor Protocol Number: TALVISUG01 Start Date*: 2013-11-21
    Sponsor Name:Consorci Mar Parc de Parc de Salut de Barcelona (Parc de Salut MAR)
    Full Title: Reducing the dose of sugammadex 50% reverse the neuromuscular blockade of rocuronium effectively after general anesthesia.
    Medical condition: Neuromuscular blockade is induced during general anesthesia, which often does not recover spontaneously, so it is necessary a pharmacological reversal. We believe that sugammadex at lower doses tha...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10057286 Neuromuscular blockade reversal PT
    14.1 10029205 - Nervous system disorders 10029315 Neuromuscular blockade PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006704-27 Sponsor Protocol Number: Bezafibrate Start Date*: 2009-07-17
    Sponsor Name:Neuromuscular Research Unit, Copenhagen University Hospital Rigshopspitalet
    Full Title: Effect of Bezafibrate on muscle metabolism during exercise in patients with fat metabolic disorders in skeletal muscle
    Medical condition: Evaluation of the effect of Bezafibrate on muscle metabolism during exercise in patients with VLCAD and CPT II deficiency
    Disease: Version SOC Term Classification Code Term Level
    12.0 10029316 Neuromuscular disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011184-36 Sponsor Protocol Number: 08/0169 Start Date*: 2009-07-14
    Sponsor Name:University College London-Joint UCLH/UCL Biomedical (R&D) Unit
    Full Title: A Phase II Randomised, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Mexiletine in Patients with Non-Dystrophic Myotonia.
    Medical condition: Non-Dystrophic Myotonia (NDM). Non-dystrophic myotonias are a group of rare neuromuscular disorders that cause episodes of muscle stiffness (known as myotonia) and paralysis. Predominantly the musc...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029317 Neuromuscular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022558-18 Sponsor Protocol Number: 2010-022558-18 Start Date*: 2010-10-11
    Sponsor Name:AZIENDA OSPEDALIERA DI PADOVA
    Full Title: A pilot trial with clenbuterol in spinal and bulbar muscular atrophy (SBMA).
    Medical condition: spinal and bulbar muscular atrophy (SBMA)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10029317 Neuromuscular disorders HLGT
    15.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    15.0 10028395 - Musculoskeletal and connective tissue disorders 10047868 Weakness of limbs LLT
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10013969 Dyspnoea at rest PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-013777-17 Sponsor Protocol Number: 1 Start Date*: 2010-02-08
    Sponsor Name:Central Manchester and Manchester University Children's Hospital NHS Trust. [...]
    1. Central Manchester and Manchester University Children's Hospital NHS Trust.
    2.
    Full Title: The effect of pamidronate treatment on bone health in patients with neuromuscular disease undergoing hip surgery.
    Medical condition: Children with neuromuscular conditions undergoing hip surgery. Aiming to identify whether pamidronate a licenced medicine mainatins bone mineral density in patients with neuromuscular conditions un...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000876-27 Sponsor Protocol Number: ATX-MTM-002 Start Date*: 2017-12-06
    Sponsor Name:Audentes Therapeutics Inc.
    Full Title: ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-L...
    Medical condition: X-linked Myotubular Myopathy (XLMTM)
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2011-004087-30 Sponsor Protocol Number: 1007612/30.04.2010 Start Date*: 2011-08-25
    Sponsor Name:Tartu University Department of Sports Medicine and Rehabilitation
    Full Title: Effect of 12 weeks rehabilitation (aspect of neuromuscular physical therapy) in middle-aged patients in post-atroscopic period
    Medical condition: Cartilage Lesion of the Knee Joint
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10023476 Knee osteoarthritis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000436-74 Sponsor Protocol Number: 432 Start Date*: 2007-11-27
    Sponsor Name:Poissy Hospital
    Full Title: Impact of two glucose control regimens by insulin on hospital mortality in intensive care unit patients (INSUREA Study)
    Medical condition: hyperglycemia in critical care unit patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018424 Glucose metabolism disorders (incl diabetes mellitus) HLGT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001734-17 Sponsor Protocol Number: FuMA Start Date*: 2014-04-23
    Sponsor Name:University of Rome Foro Italico
    Full Title: Short-term effects of testosterone enhantate and gel on neuro-physiological function
    Medical condition: HYPOGONADISM
    Disease: Version SOC Term Classification Code Term Level
    16.1 10014698 - Endocrine disorders 10058359 Hypogonadism PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001294-25 Sponsor Protocol Number: IPOXVILI Start Date*: 2018-07-26
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Regional Hypo-perfusion as metabolic raiser of ventilator-induced lung injury (VILI): pilot clinica trial
    Medical condition: Severe Acute Respiratory Distress Syndrome (ARDS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038651 Respiration failure LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10001053 Acute respiratory failure PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10038738 Respiratory, thoracic and mediastinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005792-16 Sponsor Protocol Number: Rocuronium_HVR_OSAS Start Date*: 2012-02-10
    Sponsor Name:Karolinska University Hospital
    Full Title: Effect of reduced cholinergic transmission by rocuronium on the hypoxic ventilatory response in patients with obstructive sleep apnea - before and after three months of continous positive airway pr...
    Medical condition: Obstuctive sleep apnea and acute hypoxic ventilatory response
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10055577 Obstructive sleep apnea syndrome LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000323-27 Sponsor Protocol Number: CV-0003 Start Date*: 2017-08-03
    Sponsor Name:CuraVac Europe SA
    Full Title: A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG0...
    Medical condition: Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles. The underlying defect is a decrease in the number of available acetylcho...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004696-12 Sponsor Protocol Number: FACIALPARALYSIS Start Date*: 2020-01-15
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Clinical, Instrumental and Histological evaluation of the combined use of Onabotulinumtoxin A and hyaluronic acid fillers in patients with facial paralysis
    Medical condition: hemifacial paralysis (3 to 6 of the House-Brackmann scale)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10016060 Facial palsy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004803-15 Sponsor Protocol Number: 5051-102 Start Date*: 2023-09-18
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: An Open-Label Extension Study for Patients with Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-002836-30 Sponsor Protocol Number: 22218MFPF-Weave Start Date*: 2023-03-15
    Sponsor Name:Vrije Universiteit Brussel
    Full Title: Investigating fundamental mechanisms of mental and physical fatigue using neurotransmitter reuptake inhibitors and electroencephalography: a randomized counterbalanced crossover trial
    Medical condition: Acute mental and physical fatigue in healthy participants
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002663-10 Sponsor Protocol Number: 232SM203 Start Date*: 2020-03-27
    Sponsor Name:Biogen Idec Research Limited
    Full Title: Escalating Dose and Randomized, Controlled Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy
    Medical condition: Muscular Atrophy, Spinal
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LV (Completed) IE (Completed) HU (Completed) PL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) GR (Completed) IT (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-001294-84 Sponsor Protocol Number: OPBGC&RS2011-004_CA2012 Start Date*: 2012-09-03
    Sponsor Name:EDISON PHARMACEUTICALS INC.
    Full Title: Prospective open label trial to evaluate the maintenance of the efficacy and the long term safety of EPI-743 in children with Leigh Disease
    Medical condition: Leigh Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000750-35 Sponsor Protocol Number: BP39055 Start Date*: 2018-03-02
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A TWO-PART SEAMLESS, MULTI-CENTER RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF RO7034067 IN TYPE 2 ...
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed) BE (Completed) DE (Completed) FR (Ongoing) PL (Completed) HR (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-005001-39 Sponsor Protocol Number: 4658-us-202 Start Date*: 2017-03-16
    Sponsor Name:Sarepta Therapeutics, Inc.
    Full Title: Open-Label, Multiple-Dose, Efficacy, Safety, and Tolerability Study of Eteplirsen in Subjects with Duchenne Muscular Dystrophy who Participated in Study 4658-us-201
    Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005749-30 Sponsor Protocol Number: 2015-00887 Start Date*: 2016-06-23
    Sponsor Name:Karolinska Institutet
    Full Title: A randomized, doubleblind, placebo-controlled multicenter trial to evaluate the safety and efficacy of rituximab (Mabthera) in subjects with new onset myasthenia gravis; the RINOMAX study
    Medical condition: New onset myasthenia gravis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 17:05:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA